Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
M Baccarani, G Saglio, J Goldman, A Hochhaus… - Blood, 2006 - ashpublications.org
The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and …
H Kantarjian, C Schiffer, D Jones… - Blood, The Journal of …, 2008 - ashpublications.org
The management of hematologic malignancies, including chronic myeloid leukemia (CML),
chronic lymphocytic leukemia (CLL), and acute lymphocytic leukemia (ALL), has led the way …
chronic lymphocytic leukemia (CLL), and acute lymphocytic leukemia (ALL), has led the way …
[HTML][HTML] Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial
Purpose We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in
Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term …
Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term …
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
E Jabbour, HM Kantarjian, G Saglio… - Blood, The Journal …, 2014 - ashpublications.org
This analysis explores the impact of early cytogenetic and molecular responses on the
outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) in the phase …
outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) in the phase …
[HTML][HTML] Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with …
Purpose We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in
chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular …
chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular …
Validation of the 2-ΔΔCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts
A Arocho, B Chen, M Ladanyi… - Diagnostic Molecular …, 2006 - journals.lww.com
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder that is
characterized by the presence of a reciprocal translocation between chromosomes 9 and 22 …
characterized by the presence of a reciprocal translocation between chromosomes 9 and 22 …
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
FJ Giles, PD Le Coutre, J Pinilla-Ibarz, RA Larson… - Leukemia, 2013 - nature.com
Nilotinib (Tasigna) is a BCR–ABL1 tyrosine kinase inhibitor approved for the treatment of
patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase …
patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase …
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
In chronic myeloid leukemia (CML) patients, a breakpoint cluster region–Abelson (BCR-
ABL1) value> 10% at 3 months of therapy is statistically associated with poorer outcome, yet …
ABL1) value> 10% at 3 months of therapy is statistically associated with poorer outcome, yet …
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial
H Kantarjian, R Pasquini… - Blood, The Journal …, 2007 - ashpublications.org
Therapeutic options for chronic myelogenous leukemia (CML) resistant to 400 to 600 mg
imatinib are limited. Escalating imatinib doses may overcome resistance. Dasatinib, a …
imatinib are limited. Escalating imatinib doses may overcome resistance. Dasatinib, a …
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Recent studies have demonstrated that some patients with chronic myeloid leukemia (CML)
can maintain remission after discontinuation of imatinib. A prerequisite is stable …
can maintain remission after discontinuation of imatinib. A prerequisite is stable …